/주식/ENVB
ENVB

ENVB

USD

Enveric Biosciences Inc. Common Stock

$5.700-0.400 (-6.557%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$6.100

고가

$6.645

저가

$5.520

거래량

0.25M

기업 기본 정보

시가총액

3.0M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.07M

거래소

NCM

통화

USD

52주 범위

저가 $5.52현재가 $5.700고가 $1444.5

관련 뉴스

BusinessWire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic

더 보기
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
BusinessWire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that

더 보기
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
BusinessWire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or

더 보기
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
BusinessWire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or

더 보기
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications